IMUX logo

IMUX
Immunic Inc

12,647
Mkt Cap
$172.38M
Volume
161,735.00
52W High
$15.10
52W Low
$5.06
PE Ratio
-2.00
IMUX Fundamentals
Price
$12.08
Prev Close
$12.66
Open
$12.36
50D MA
$11.39
Beta
1.44
Avg. Volume
319,823.35
EPS (Annual)
-$6.24
P/B
1.09
Rev/Employee
$0.00
$68.18
Loading...
Loading...

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available

Earnings Recap

Immunic expects to fund operations into late 2027 with $200M from a private placement, targeting NDA submission in mid-2027 and regulatory approval in 2028 for vidofludimus calcium.

Bullish

Immunic secured $200M in private placement funding, extending its operational runway into late 2027. The company strengthened its leadership team and progressed vidofludimus calcium in Phase 3 trials and pipeline expansion.

Bearish

Immunic experienced increased R&D and G&A expenses, leading to a wider net loss of $32.6M for Q1 2026. The company is also exploring strategic alternatives for its IMU-856 program.

Latest IMUX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.